News

This Phase I award offers Avaxia a sum of around $145,000 in research and development funds. Avaxia founder and CEO Barbara Fox said they are delighted to have

Vosaroxin, formerly known as voreloxin, is a first-in-class anticancer quinolone derivative, or AQD, a class of compounds that has not been used previously for the treatment of cancer.

The preliminary Phase I results for the EV71 vaccine in adults showed a good safety profile and preliminary immunogenicity profile. Sinovac subsequently initiated the inoculations in the young

The double-blind, randomized, placebo-controlled Phase 2a study of VX-765 enrolled 60 people with treatment-resistant partial onset epilepsy. The primary endpoint of the study was safety and tolerability, and

With this approval, Herceptin is now available for patients with HER2-positive advanced or recurrent gastric cancer and HER2-positive breast cancer (advanced or recurrent / postoperative adjuvant chemotherapy) in

The branded generics and OTC product portfolio of PharmaSwiss is expected to strengthen Valeant’s presence in the region. Reportedly, the senior management team of PharmaSwiss will remain with

As per the terms of the agreement, Epizyme is entitled to get an upfront payment including research, development and sales milestones and royalties to Eisai as the project

Talon claims Marqibo is a novel, targeted Optisome encapsulated formulation product candidate of the FDA-approved anticancer drug Vincristine. The company is developing Marqibo as a treatment for Ph-

Zidovudine tablets are used in conjunction with other medications for controlling HIV infection and are also indicated for the prevention of mother-to-child HIV-1 transmission. The product is included